Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudio Scuoppo

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Cancer Cell|September 19, 2019
LMO2 as a Biomarker for Hypersensitivity to Genotoxic TherapyClaudio Scuoppo, Shan Zha
Scientific Reports|December 17, 2016
A CRISPR/Cas9 Functional Screen Identifies Rare Tumor SuppressorsAlexandra Katigbak, Regina Cencic, Francis Robert, et al.
Biotechniques|October 15, 2014
Lentiviral-based approach for the validation of cancer therapeutic targets in vivoChiara Ambrogio, Patrick Stern, Claudio Scuoppo, et al.
Biomedicines|February 25, 2023
A New Insight into MYC Action: Control of RNA Polymerase II Methylation and Transcription TerminationFiorella Scagnoli, Alessandro Palma, Annarita Favia, et al.
Blood Cancer Discovery|August 6, 2024
Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell LymphomaClaudio Scuoppo, Bowen Cai, Kenneth Ofori, et al.
ACS Chemical Biology|February 27, 2024
Exponential Combination of <i>a</i> and <i>e/g</i> Intracellular Peptide Libraries Identifies a Selective ATF3 InhibitorMiao Yu, T M Simon Tang, Lila Ghamsari, et al.
Experimental Cell Research|May 11, 2007
The oncogenic transcription factor PAX3-FKHR can convert fibroblasts into contractile myotubesClaudio Scuoppo, Ilan Riess, Michel Schmitt-Ney, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 7, 2019
Repurposing dasatinib for diffuse large B cell lymphomaClaudio Scuoppo, Jiguang Wang, Mirjana Persaud, et al.
Cancer Research|May 3, 2006
Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcomaRiccardo Taulli, Claudio Scuoppo, Francesca Bersani, et al.
Cancer Gene Therapy|February 19, 2005
RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met-mediated tumorigenesisRiccardo Taulli, Paolo Accornero, Antonia Follenzi, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Cancer Cell|September 19, 2019
LMO2 as a Biomarker for Hypersensitivity to Genotoxic TherapyClaudio Scuoppo, Shan Zha
Scientific Reports|December 17, 2016
A CRISPR/Cas9 Functional Screen Identifies Rare Tumor SuppressorsAlexandra Katigbak, Regina Cencic, Francis Robert, et al.
Biotechniques|October 15, 2014
Lentiviral-based approach for the validation of cancer therapeutic targets in vivoChiara Ambrogio, Patrick Stern, Claudio Scuoppo, et al.
Biomedicines|February 25, 2023
A New Insight into MYC Action: Control of RNA Polymerase II Methylation and Transcription TerminationFiorella Scagnoli, Alessandro Palma, Annarita Favia, et al.
Blood Cancer Discovery|August 6, 2024
Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell LymphomaClaudio Scuoppo, Bowen Cai, Kenneth Ofori, et al.
ACS Chemical Biology|February 27, 2024
Exponential Combination of <i>a</i> and <i>e/g</i> Intracellular Peptide Libraries Identifies a Selective ATF3 InhibitorMiao Yu, T M Simon Tang, Lila Ghamsari, et al.
Experimental Cell Research|May 11, 2007
The oncogenic transcription factor PAX3-FKHR can convert fibroblasts into contractile myotubesClaudio Scuoppo, Ilan Riess, Michel Schmitt-Ney, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 7, 2019
Repurposing dasatinib for diffuse large B cell lymphomaClaudio Scuoppo, Jiguang Wang, Mirjana Persaud, et al.
Cancer Research|May 3, 2006
Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcomaRiccardo Taulli, Claudio Scuoppo, Francesca Bersani, et al.
Cancer Gene Therapy|February 19, 2005
RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met-mediated tumorigenesisRiccardo Taulli, Paolo Accornero, Antonia Follenzi, et al.
Pageof 3